Quest Diagnostics (DGX)

Quest Diagnostics (DGX) Stock Quote Information

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. It offers access to diagnostic testing services through its network of laboratories and patient service centers; and interpretive consultation to patients and physicians. The company provides commercial clinical testing services, including routine clinical testing for blood chemistries, complete blood cell counts, urinalyses, pregnancy and other prenatal tests, microbiology testing, alcohol and other substance-abuse tests, and allergy tests; cancer diagnostics, such as anatomic pathology services; and gene-based and other esoteric testing, as well as various risk assessment services for insurance companies. It also provides central laboratory testing in connection with clinical research trials on new drugs, vaccines, and certain medical devices; and clinical testing to employers for the detection of employee use of drugs-of-abuse. In addition, Quest Diagnostics develops and manufactures products that enable healthcare professionals to make healthcare diagnoses, including HerpeSelect ELISA tests that detect patient antibodies to certain types of Herpes Simplex virus, and sells to academic medical centers, hospitals, and commercial laboratories; White Blood Cell Analyzer, a whole-blood test performed on finger-stick samples for providing a total white blood cell count; and InSure fecal immunochemical test for screening for colorectal cancer. Further, it develops and integrates clinical connectivity and data management solutions for healthcare organizations, physicians, and clinicians through its Care360 suite of products; offers the ChartMaxx electronic document management system for hospitals; and has capabilities to deploy a health information exchange system enabling healthcare providers to access and manage patient data. The company was founded in 1967 and is headquartered in Madison, New Jersey.